- Conditions
- Parkinson's Disease
- Interventions
- 2 mg perampanel, 4 mg perampanel, placebo comparator
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 82 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 51
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease
- Interventions
- APL-130277, APO-go, Apokyn
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boca Raton, Florida • Port Charlotte, Florida • Farmington Hills, Michigan
- Conditions
- Parkinson's Disease
- Interventions
- rasagiline mesylate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 6
- States / cities
- Fresno, California • Chicago, Illinois • Omaha, Nebraska + 3 more
- Conditions
- Parkinson's Disease, Off Episodes of Parkinson Disease
- Interventions
- APL-130277, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
- Conditions
- PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
- Interventions
- SER-252 (PEOZ-apomorphine), enFuse
- Drug · Device
- Lead sponsor
- Serina Therapeutics
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
- Conditions
- Parkinson's Disease
- Interventions
- Lu AF28996, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Farmington Hills, Michigan • Round Rock, Texas
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Tozadenant
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- ExAblate Pallidotomy, Sham ExAblate Pallidotomy
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 11
- States / cities
- Stanford, California • Boynton Beach, Florida • Baltimore, Maryland + 7 more
- Conditions
- Parkinson's Disease
- Interventions
- E2007
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Oxnard, California • New Haven, Connecticut + 7 more
- Conditions
- Parkinson's Disease
- Interventions
- ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
- Combination Product · Drug
- Lead sponsor
- NeuroDerm Ltd.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Parkinson's Disease
- Interventions
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 7
- States / cities
- Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Parkinson Disease
- Interventions
- Tavapadon, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 507 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
- Conditions
- Parkinson Disease, Off Episodes
- Interventions
- APL-130277, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
- Conditions
- Parkinson's Disease (PD)
- Interventions
- ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
- Drug · Device
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years to 99 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more
- Conditions
- Parkinson Disease
- Interventions
- IPX203
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Parkinson's Disease
- Interventions
- DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
- Drug
- Lead sponsor
- Dart NeuroScience, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 9
- States / cities
- Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- CVT-301, Placebo
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
- Conditions
- Parkinson's Disease
- Interventions
- VY-AADC02, Sham (Placebo) Surgery
- Biological · Other
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 8 more
- Conditions
- Parkinson Disease
- Interventions
- Placebo, UCB0022
- Other · Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 61
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Interventions
- clartihromycin, amoxicillin, and omeprazole, placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson's Disease
- Interventions
- PF-06649751
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
- Conditions
- Parkinson Disease, Motor Disorder
- Interventions
- BTRX-246040, Placebo
- Drug
- Lead sponsor
- BlackThorn Therapeutics, Inc.
- Industry
- Eligibility
- 30 Years to 76 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Hallandale, Florida • Farmington Hills, Michigan • Durham, North Carolina + 1 more
- Conditions
- Parkinson Disease
- Interventions
- CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas